1.Expanding the concept of patient-derived xenografts cohorts in head and neck cancer: current and future perspectives.
West China Journal of Stomatology 2021;39(6):617-623
Head and neck cancer is the seventh common cancer in the world, and various existing treatment strategies provide modest benefit for most patients with head and neck cancer. Meanwhile, therapeutic strategies lacking molecular typing significantly hinder the development of individualized treatment for head and neck cancer. In recent years, connected by preclinical models, the novel ideal has gradually reached a consensus in terms of facilitating inter-transformation of clinical problems and basic achievements. As a bridge between basic research and clinical transformation, patient-derived xenografts (PDX) models precisely replicate genetic characteristics and tumor evolution, which are displaying great vitality in elucidating the mechanism of tumorigenesis and progression. Moreover, cohorts composed of several PDX models highlight the unique advantages of mice for drug screening and biomarker analysis for patients. This ideal preclinical model explores potential treatment strategies suited the ethical standards as much as possible for patients.
Animals
;
Disease Models, Animal
;
Head and Neck Neoplasms
;
Heterografts
;
Humans
;
Mice
;
Xenograft Model Antitumor Assays
2.Effects of hyperbaric oxygen on tumor growth in the mouse model of LNCaP prostate cancer cell line.
Hao TANG ; Zheng-Yu ZHANG ; Jing-Ping GE ; Wen-Quan ZHOU ; Jian-Ping GAO
National Journal of Andrology 2009;15(8):713-716
OBJECTIVETo assess the safety of hyperbaric oxygen in the treatment of radiation-induced hemorrhagic cystitis in patients with prostate cancer, and to investigate its effect on the growth of indolent prostate cancer in vivo.
METHODSThirty severe combined-immunodeficient mice received subcutaneous injection of human prostate cancer LNCaP cells. Then they were randomized to an experimental and a control group and exposed to 20 sessions of hyperbaric oxygen and normobaric air, respectively, followed by a 4-week observation on the growth of the transplanted tumors and analyses of their histopathological features at 28 days, including the volume, microvessel density (CD34), apoptosis markers (p53 and p27 proteins) and the proliferation index (Ki-67) of the LNCaP tumors.
RESULTSOn the 28th day after tumor vaccination, the tumor volume was (120 +/- 7.9) mm3 in the HBO and (122 +/- 8.2) mm3 in the control group; the microvessel density and the expressions of Ki-67, p53 and p27 were 39.3 +/- 5.2, (78.1 +/- 7.6)%, (40.4 +/- 6.2)% and (63.7 +/- 5.1)% in the former, and 36.2 +/- 4.9, (75.3 +/- 8.4)%, (44.2 +/- 5.7)% and (61.5 +/- 5.5)% in the latter. There were no significant differences in all the indexes above between the two groups (P > 0.05).
CONCLUSIONHyperbaric oxygen did not promote the growth of indolent prostate cancer in the murine model, nor did it have any significant effect on the new vessels.
Animals ; Cell Line, Tumor ; Humans ; Hyperbaric Oxygenation ; Male ; Mice ; Mice, SCID ; Prostatic Neoplasms ; Xenograft Model Antitumor Assays
4.Quantitative Assessment of Tumor Responses after Radiation Therapy in a DLD-1 Colon Cancer Mouse Model Using Serial Dynamic Contrast-Enhanced Magnetic Resonance Imaging.
Sung Jun AHN ; Woong Sub KOOM ; Chan Sik AN ; Joon Seok LIM ; Seung Koo LEE ; Jin Suck SUH ; Ho Taek SONG
Yonsei Medical Journal 2012;53(6):1147-1153
PURPOSE: The purpose of this study was to investigate the predictability of pretreatment values including Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) derived parameters (Ktrans, Kep and Ve), early changes in parameters (Ktrans, tumor volume), and heterogeneity (standard deviation of Ktrans) for radiation therapy responses via a human colorectal cancer xenograft model. MATERIALS AND METHODS: A human colorectal cancer xenograft model with DLD-1 cancer cells was produced in the right hind limbs of five mice. Tumors were irradiated with 3 fractions of 3 Gy each for 3 weeks. Baseline and follow up DCE-MRI were performed. Quantitative parameters (Ktrans, Kep and Ve) were calculated based on the Tofts model. Early changes in Ktrans, standard deviation (SD) of Ktrans, and tumor volume were also calculated. Tumor responses were evaluated based on histology. With a cut-off value of 0.4 for necrotic factor, a comparison between good and poor responses was conducted. RESULTS: The good response group (mice #1 and 2) exhibited higher pretreatment Ktrans than the poor response group (mice #3, 4, and 5). The good response group tended to show lower pretreatment Kep, higher pretreatment Ve, and larger baseline tumor volume than the poor response group. All the mice in the good response group demonstrated marked reductions in Ktrans and SD value after the first radiation. All tumors showed increased volume after the first radiation therapy. CONCLUSION: The good response after radiation therapy group in the DLD-1 colon cancer xenograft nude mouse model exhibited a higher pretreatment Ktrans and showed an early reduction in Ktrans, demonstrating a more homogenous distribution.
Animals
;
Colonic Neoplasms/*pathology/*radiotherapy
;
Female
;
Humans
;
Magnetic Resonance Imaging/*methods
;
Mice
;
Mice, Nude
;
Xenograft Model Antitumor Assays
5.Pharmacological effects of site specific conjugated anti-human epidermal growth factor receptor 2-antibody drug conjugate using unnatural amino acid technology.
Xue Jun LIANG ; Li Ying GONG ; Fei ZHOU ; De Min ZHOU ; Jing Jing ZHU
Journal of Peking University(Health Sciences) 2019;51(5):797-804
OBJECTIVE:
To investigate inhibitory activities of a homogenous anti-human epidermal growth factor receptor 2 (HER2)-antibody drug conjugate (ADC) on the proliferation of nine tumor cell lines with different levels of HER2 expressions, and its activities on the tumor growth of five xenograft mouse models.
METHODS:
The HER2 expression levels of BT-474, Calu-3, MCF-7, MDA-MB-231, MDA-MB-468, SK-BR-3, SK-OV-3, HCC1954, NCI-N87 tumor cell lines were measured using QIFI KIT. For the in vitro anti-proliferation assay, serial diluted anti-HER2-ADC, ado-trastuzumab emtansine, AS269, pAF-AS269 and paclitaxel were added to the seeded cells, and after 72 or 96 hours of incubation, the cell proliferation was analyzed. For the in vivo activity, 5-6 weeks old mice were inoculated with four HER2 positive tumor cell lines HCC1954, BT-474, SK-OV-3, NCI-N87 or one HER2 negative tumor cell line MDA-MB-468. Different amounts of anti-HER2-ADC, ado-trastuzumab emtansine, trastuzumab, paclitaxel and phosphate buffered saline control were injected after the tumor volume reached a certain size, then the tumor growth inhibition was analyzed.
RESULTS:
The expression levels of the six high HER2-expression cell lines SK-OV-3, NCI-N87, SK-BR-3, Calu-3, HCC1954, BT-474 were between 430 000 to 800 000 receptors per cell, which were 50 times higher than those of the other three low HER2 expression tumor cell lines MDA-MB-231, MCF-7, MDA-MB-468. Anti-HER2-ADC had inhibition effects on cell lines with high level of HER2 expression in the in vitro anti-proliferation assay. The half maximal inhibitory concentrations of anti-HER2-ADC on SK-OV-3, NCI-N87, SK-BR-3, Calu-3, HCC1954, BT-474 tumor cell lines were 46 pmol/L, 17 pmol/L, 17 pmol/L, 161 pmol/L, 125 pmol/L, 50 pmol/L, respectively. Anti-HER2-ADC had a dose dependent antitumor activity in vivo in all the HER2 positive xenograft mouse models. In NCI-N87 xenograft tumor model, the same dose of anti-HER2-ADC showed better anti-tumor activity compared with trastuzumab and ado-trastuzumab emtansine, and its relative tumor proliferation rates were about 1/30 to 1/20 of the two. In HCC1954 xenograft tumor model, the complete regression of the tumor was observed. As expected, anti-HER2-ADC had no tumor inhibitory effects on MDA-MB-468 xenograft models with low HER2 expression. The antitumor activities of anti-HER2-ADC in HER2 positive xenograft tumor models were the same as or better than the activities of ado-trastuzumab emtansine.
CONCLUSION
The homogenous site-specific anti-HER2-ADC obtained using unnatural amino acid technology can inhibit the growth of high HER2-expression tumor cells with high potency both in vivo and in vitro.
Amino Acids
;
Animals
;
Breast Neoplasms
;
Cell Line, Tumor
;
Humans
;
Immunoconjugates
;
Mice
;
Receptor, ErbB-2
;
Trastuzumab
;
Xenograft Model Antitumor Assays
6.Roles of Newcastle disease virus in human acute monocytic leukemia in vitro and in vivo.
Ya-Jun WANG ; Chun SONG ; Xiao-Hui LI ; Jian-Bai ZHANG
Chinese Journal of Contemporary Pediatrics 2011;13(2):149-152
OBJECTIVESome research has shown that Newcastle disease virus (NDV) is effective in the treatment of various tumors, including transferred melanoma and well differentiated renal cell carcinoma. This study aimed to evaluate the effect of NDV against human acute monocytic leukemia SHI-1 cells in vitro and in vivo.
METHODSIn vitro, the density and morphologic changes between wild SHI-1 cells (control) and NDV-infected SHI-1 cells were observed. MTT assay was utilized to observe the effect of NDV on the proliferation of SHI-1 cells. In vivo, the effect of NDV on the tumor inhibition was assessed using SHI-1 xenografts subcutaneously established in CD-1 nude mice. NDV was given by intra-tumor injections, and the tumor inhibition rate and toxic effects were evaluated.
RESULTSIn the control group, the SHI-1 cells were observed using an inverted microscope to be regular in morphology and intensive in distribution. In the NDV-infected group, the SHI-1 cells were irregular and sparsate, and the aggregate and fused cells were common. MTT assay showed that the proliferation of SHI-1 cells were significantly inhibited by NDV at different concentrations (P<0.01) and in a time- and concentration-dependent manner. The tumor inhibition rate in the NDV group was 84.7%, which was significantly higher than that in the control group (P<0.01). No toxic effects were observed in the nude mice.
CONCLUSIONSNDV can suppress the proliferation of human acute monocytic leukemic cells both in vitro and in vivo. The safety of NDV is reliable.
Animals ; Cell Proliferation ; Humans ; Immunotherapy, Active ; Leukemia, Monocytic, Acute ; therapy ; Mice ; Mice, Nude ; Newcastle disease virus ; physiology ; Xenograft Model Antitumor Assays
7.Establishment of bone metastasis model of prostate cancer in nude mice by intratibia injection of human prostate cancer cell line Du145.
Yong LUO ; Lin-Lin ZHANG ; Liang NING ; Da-Lin HE ; Jin-Hai FAN ; Hui-Lian HOU
National Journal of Andrology 2006;12(2):133-136
OBJECTIVETo establish a bone metastasis model of prostate cancer by intratibia injection of Du145 in nude mice, observe the local growth of tumor in tibia and then assess application value of this model.
METHODSFor 9 male nude mice, Du145 (5 x 10(6)) was injected in tibia by a TB syringe with a 29-gauge needle at a dose of 30 microl per mouse. Then the vital signs of the nude mice were observed. When the mice were dying, they were sacrificed, and the tissues of right hindlimbs, lymphatic nodes, lungs and livers were taken out, fixed in 10% formalin, embedded in paraffin, stained by HE and then observed microscopically.
RESULTSIncidence of bone tumor after intratibia injection was 67% (6 out of 9). About 48 days later, there were some small palpable nodes in right hind-limbs of the 6 mice and they couldn't walk normally. About 55 days later, cachexia occurred in them. After dissection, some carrion-like tissue grew from marrow cavity to muscular spatium, which was identified as tumor tissue by HE. The envelop of livers became crampy, and acute hepatitis could be diagnosed through microscopy, which represented a large scale of hepatocytic death, liver sinus dilatation and hyperemia, hepatic lobule infiltrated by lymphocyte, macrophage and inconspicuous hyperplasia. Since hypohepatia occurred too early, we couldn't detected distant metastases.
CONCLUSIONThe intratibia injection model is an optimal animal model to study metastasis of prostate cancer. It mimics the natural situation of human prostate cancer and will help to understand the mechanisms of androgen-independence and osseous metastasis, and tumor-host determinants of PSA expression.
Animals ; Bone Neoplasms ; secondary ; Humans ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Prostatic Neoplasms ; pathology ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays ; methods
9.Establishment of red fluorescent protein orthotopic transplantation nude mice metastasis model of pancreatic cancer and whole-body fluorescent imaging.
Ze-qian YU ; Jia-hua ZHOU ; Ke-tao TAO ; Liang HU ; Jie ZHENG ; De-tong YANG
Chinese Journal of Surgery 2009;47(14):1092-1095
OBJECTIVETo establish a stable high red fluorescent protein (RFP)-expressing orthotopic transplantation nude mice spontaneous metastasis model of pancreatic cancer.
METHODSStable high RFP-expressing cells SW1990-RFP were injected subcutaneously into mice to establish subcutaneous implantation model. Fluorescent tumor piece from subcutaneous was transplanted into the body of the pancreas to establish surgical orthotopic implantation model. The growth of primary tumor, metastasis and micrometastasis were assessed by whole-body fluorescence imaging system.
RESULTSTwelve RFP orthotopic transplantation nude mice metastasis models of pancreatic cancer were established successfully, the percentage of success rate was 100%. RFP-labeled pancreatic cancer growth could be monitored in real time way. The micrometastasis of primary lesions were detected in early stage with whole-body fluorescence imaging system.
CONCLUSIONSThe RFP orthotopic transplantation nude mice metastasis model of pancreatic cancer is stable and reliable, and can be observed dynamically in vitro in a noninvasive way, with much higher sensitivity and specificity.
Animals ; Disease Models, Animal ; Female ; Luminescent Proteins ; Male ; Mice ; Mice, Nude ; Neoplasm Metastasis ; Pancreas ; pathology ; Pancreatic Neoplasms ; pathology ; Xenograft Model Antitumor Assays
10.Establishment and characteristics of orthotopically transplanted model of human primary malignant spleen lymphoma in nude mice.
Qiuzhen LIU ; Wei ZHAO ; Chaowei TUO ; Zihong WANG ; Bingquan WU ; Ning ZHANG
Chinese Journal of Oncology 2002;24(3):234-238
OBJECTIVETo establish three orthotopically transplanted model of human primary malignant spleen lymphoma in the nude mice.
METHODSOrthotopic transplantation of histologically intact human primary malignant splenic lymphoma tissue obtained from patients was introduced into the splenic parenchyma of nude mice. Tumorigenicity, invasion, metastasis and morphological characteristics of the transplanted tumor were studied by light microscopy, electron microscopy and immunohistochemical methods.
RESULTSThe first kind, a strain of human primary malignant spleen lymphoma (non-Hodgkin's, cleaved B cell, BFNHL-HMN-1) screened from 11 patients which had been passaged in vivo for 41 generations, a second kind, a liver metastasis model of human primary malignant spleen lymphoma (non-Hodgkin's, cleaved B cell, LM-BFNHL-HMN-2) which had been passaged for 47 generations and a third kind of human primary malignant spleen lymphoma (non-Hodgkin's, T-immunoblastic cell, TINHL-HMN-3) having passaged for 37 generations were all successfully transplanted in 611 nude mice. Models of BFNHL-HMN-1 and TINHL-HMN-3 tumor gave nodular growth and lymph node metastasis in the spleen hilum but without any metastasis in the abdominal lymph nodes or organs. In the LM-BFNHL-HMN-2 model, not only did the tumor cells grow in the spleen, but in spleen hilum, lymph nodes and liver also. The orthotopically transplanted tumor cells were similar to the original human tumor in light histopathology, ultrastructure features, DNA content and chromosomal karyotype.
CONCLUSIONThese three models are able to serve as useful tools for the study of biologic characteristics and experimental treatment of human primary malignant lymphoma.
Animals ; Disease Models, Animal ; Humans ; Lymphoma ; pathology ; Mice ; Mice, Nude ; Neoplasm Metastasis ; Neoplasm Transplantation ; Splenic Neoplasms ; pathology ; Xenograft Model Antitumor Assays